Weill Cornell Lymphoma Program

Home
United States
New York, NY
Weill Cornell Lymphoma Program

Enabling patients with lymphoma to have the best possible clinical outcomes.

The Lymphoma Program at Weill Cornell Medical College/NewYork-Presbyterian Hospital, located on the Upper East Side of New York City, is internationally recognized for our efforts to enable patients with non-Hodgkin’s lymphoma, Hodgkin’s disease and related disorders to have the best possible clinical outcome, including cure when possible. The goal of our page and blog is to provide you with up-to-date information about the latest developments in lymphoma treatment and research.

11/07/2025

Dr. Sarah Rutherford’s talk at on a combination therapy for was mentioned as one of the most notable conference presentations in this Healio video:

In this video, Leo I. Gordon, MD, FACP, discusses notable presentations from Lymphoma, Leukemia & Myeloma Congress.

10/31/2025

Dr. Sarah Rutherford outlined strategies for treating elderly patients with including how she approaches treatment and the use of combination and regimens: https://bit.ly/47sAife

$Watch Dr. Erin Mulvey explain emerging treatments for relapsed/refractory Follicular at : https://bit.ly/4nkXMZH (cc:...$

10/29/2025

Watch Dr. Erin Mulvey explain emerging treatments for relapsed/refractory Follicular at : https://bit.ly/4nkXMZH (cc: Oncology Learning Network)

Erin Mulvey, MD, discusses novel treatment options for patients with relapsed/refractory follicular lymphoma at the 2025 Lymphoma, Leukemia & Myeloma Congress.

10/21/2025

Join Dr. Peter Martin tomorrow 10/22 for a Lymphoma Research Foundation webinar diving into everything you need to know about Mantle Cell , including symptoms, treatment options, clinical trials, quality of life, and more. Register here: https://bit.ly/3IWj8Pb

10/10/2025

Listen to Dr. John Allan speak with OncLive about what factors influence treatment decision-making for patients with chronic lymphocytic leukemia ( ):

Allan and Rubianes discuss factors that influence treatment decision-making for patients with chronic lymphocytic leukemia.

10/03/2025

Join Dr. Peter Martin on Tuesday, October 7 for a webinar hosted by The Patient Story where he’ll be answering the most important questions about living with . Register here to hear his expert insights:

Got questions about follicular lymphoma? Dr. Peter Martin answers what matters most to patients in this expert Q&A. Register now to join.

08/08/2025

ICYMI: the combination of nivolumab + AVD outperformed a brentuximab vedotin based regimen in older patients with classic according to led by Dr. Sarah Rutherford: https://bit.ly/3UHaGW0 (cc: Targeted Oncology)

A recent trial reveals that nivolumab combined with chemotherapy significantly improves survival rates in older patients with advanced Hodgkin lymphoma.

08/06/2025

led by Dr. Sarah Rutherford compared two different combination treatment regimens for advanced classical patients over the age of 60:

In a subset analysis from the phase III SWOG S1826 trial reported in the Journal of Clinical Oncology, Rutherford et al compared the survival outcomes of nivolumab plus AVD vs brentuximab vedotin plus...

06/27/2025

Results from a showed that second-line sintilimab plus beat chemotherapy alone in subset of patients. Dr. Sarah Rutherford commented on these results:

Use of the PD-1 inhibitor sintilimab in combination with ICE chemotherapy as a second-line treatment in classical Hodgkin lymphoma shows impressive response rates vs chemo alone in the phase 3 ORIENT-21 trial.

$Dr. Sarah Rutherford weighed in on presented at evaluating a new combination therapy regiment for relapsed or refrac...$

06/25/2025

Dr. Sarah Rutherford weighed in on presented at evaluating a new combination therapy regiment for relapsed or refractory patients with poor prognoses:

Novel combination of acimtamig and an allogenic natural killer cell product shows safety and promising objective response rates in patients with few other remaining treatment choices.

02/11/2025

Watch Dr. Jia Ruan talk about long-term follow-up combining azacitidine with CHOP for previously untreated peripheral T-cell : https://bit.ly/3WK19yP (cc: VJHemOnc)

Jia Ruan, MD, PhD, Weill Cornell Medical College, New York City, NY, comments on the long-term follow-up of a Phase...

02/07/2025

Dr. Jia Ruan spoke with VJHemOnc about a phase 2 evaluating a novel triplet combination for mantle cell ( ):

Jia Ruan, MD, PhD, Weill Cornell Medical College, New York City, NY, comments on a Phase II trial (NCT03863184) of...

Address

520 East 70th Street, Starr Pavilion, 3rd Floor
New York, NY
10065

Website

https://cornell-lymphoma.com/

Alerts

Be the first to know and let us send you an email when Weill Cornell Lymphoma Program posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

Magnus Wellness
16 E 40th Street, Fl 4

Want your practice to be the top-listed Clinic in New York?

Our Story

The Lymphoma Program at Weill Cornell Medicine and NewYork-Presbyterian Hospital is one of the leading clinical and scientific research centers in the world. The renowned experts that comprise our team are committed to delivering compassionate, cutting-edge care to improve the lives of people with lymphoma before, during and for years after treatment.

We are not content to care only for current lymphoma patients; we also actively pursue medical advances that will alleviate the suffering of those affected by the disease in the future. Whether acting as your primary oncologist, working in tandem with your oncologist or primary physician, overseeing your participation in a clinical trial or providing a second opinion, we are pleased to help all patients achieve the best possible results.